Plaid Technologies appoints Shawn Babcock as chief operating officer

Plaid Technologies Inc. (CSE: STIF) (OTC: STIFF) (FRA: 5QX0) appointed Shawn Babcock as chief operating officer, effective January 20, 2026, according to a company statement.

Babcock brings more than nine years of senior executive leadership experience in commercializing technologies across industrial sectors, with focus on construction and materials businesses. He previously served as chief executive officer of Change Agronomy, where he developed a multi-stage agronomy and processing platform for industrial hemp production and secured financing across North America and the United Kingdom.

As chief operating officer, Babcock will oversee daily operations with emphasis on scaling and commercializing the company's cement additive and graphene dispersion technologies. His responsibilities include advancing manufacturing readiness, supply chain integration, and quality control for the company's cement additive products.

"Shawn brings exactly the operational discipline and commercialization experience we need at this stage of our growth," said Guy Bourgeois, CEO of Plaid Technologies. "His ability to commercialize emerging technologies, build scalable operations, and execute across complex supply chains will be instrumental as we move toward broader market adoption."

In connection with the appointment, subject to Canadian Securities Exchange approval, the company granted Babcock 200,000 stock options exercisable at $0.60 per share and 150,000 restricted share units. The options vest quarterly over 12 months and expire after four years. The restricted share units vest upon achieving performance milestones and also expire after four years.

Plaid Technologies focuses on developing graphene-enhanced technologies, with initial applications targeting wellbore cement and subsurface uses for its graphene-infused concrete mixture.

You May Also Be Interested In

• Kite Realty Group names new VP of capital markets and IR
• Baxter names John Rogers as CFO, effective October 2026
• Nasus Pharma CFO departs, interim replacement named